Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News

Greg Scott joined Foley's Eye on China web conference.
>> More information…

NeoStem Receives SFDA Approval for Proton Pump Inhibitor

publication date: Jan 25, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
NeoStem, Inc. said its China subsidiary, Suzhou Erye Pharmaceutical, was granted SFDA approval for omeprazole 20mg capsules. Omeprazole is a proton pump inhibitor prescribed to treat peptic ulcer disease and gastroesophageal reflux disease. The drug is on China's National Medical Reimbursement Insurance List, making it eligible for insurance reimbursement. More details...

Stock Symbol: (NYSE Amex: NBS)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
Munich, Germany
November 14, 2010
Suzhou, China
November 17-18, 2010
>>More details...
 
Partner Events

BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners